论文部分内容阅读
目的 评价分子吸附再循环系统 (MARS)治疗对炎性因子单核细胞趋化蛋白 1(MCP 1)血清质量浓度的影响。方法 通过ELISA方法 ,观察 2 0 0 2 - 12～ 2 0 0 3- 12在西安交通大学第一医院经MARS治疗的肝衰竭患者 (2 0例次 )MCP -1血清质量浓度的变化。结果 (1)MARS治疗后 ,患者临床症状及体征均有不同程度改善 ,患者病死率 4 6 . 6 7%。 (2 )MARS治疗后患者MCP 1明显降低 (P <0. 0 5 ) ,好转组下降较死亡组更为显著。在MARS治疗前亚重肝组MCP -1值较慢重肝组明显升高 ,经过MARS治疗 ,两组MCP -1值显著降低 ,亚重肝组下降更为明显。结论 MARS系统能够清除肝衰竭患者体内MCP -1,MCP- 1减少与患者预后有关 ,患者临床表现的改善与MCP- 1降低存在一致性。
Objective To evaluate the effect of molecular adsorption and recycle system (MARS) on serum concentration of inflammatory cytokine monocyte chemoattractant protein 1 (MCP 1). Methods The serum level of MCP - 1 in 20 patients with liver failure (20 cases) treated by MARS at the First Hospital of Xi’an Jiaotong University from 2000 to December 2000 was detected by ELISA. Results (1) After the treatment of MARS, clinical symptoms and signs of patients improved to varying degrees, the patient mortality rate was 46.67%. (2) The MCP 1 level in patients treated with MARS was significantly lower (P <0.05), and the decline in the improved group was more significant than that in the death group. MCP-1 in sub-heavy liver group was significantly lower than that in severe liver group before MARS treatment. After MARS treatment, the MCP-1 level decreased significantly in both groups, and the decrease in sub-heavy liver group was more obvious. Conclusion The reduction of MCP-1 and MCP-1 in patients with liver failure by MARS system is related to the prognosis of patients. There is consistency between the improvement of clinical manifestations and the decrease of MCP-1 in patients with liver failure.